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Introduction
Autoantibodies are closely associated with the pathogenesis of autoimmune diseases. For example, antibodies to the acetylcholine receptor cause myasthenia gravis (1) , and Coomb's antibodies are responsible for autoimmune hemolytic anemia (2) . This led us to speculate that specific manipulation of autoantibody production might lead to a new therapy for autoimmune diseases (3) (4) (5) .
Anti-idiotypic antibodies have the ability to regulate the production of relevant idiotype (Id)-positive antibodies in vivo as well as in vitro (6) (7) (8) . The antibodies may also make it possible to control pathogenetic antibody synthesis in autoimmune states. Along this line, several studies have demonstrated the suppressive ability of anti-Id antibodies on the synthesis of autoantibodies in vitro (3, 4, (9) (10) (11) (12) . Anti-Id immunity, however, is not a simple matter in the case of immune responses in vivo: for example, the administration of low doses of anti-Id antibodies has been shown to cause an enhanced response to dinitrophenyl (DNP) (13, 14) . Furthermore, anti-Id antibodies with internal image (Ab 2,B activity) have also elicited the production of antithyroglobulins when administered in C3H/ He mice (15) . In vivo administration of anti-Id antibodies in NZB/W F. mice has induced the transient suppression of anti-DNA synthesis, which is, however, replaced by Id-negative anti-DNA production (16) . A similar trial had no effect on MRL/lpr mice (17) . This may be attributed to the complexity of anti-Id immunity in vivo; anti-Id antibodies might work not only on clones with regulatory ability, but also on those with an enhancing capacity in the immune network system, resulting in dual effects on immune responses in vivo (16, 18) . Another problem is in the choice of anti-Id antibodies, which should have the ability to target specific pathogenetic anti-DNA antibodies among numerous antibodies. Thus, therapeutic application of anti-Id immunity to autoimmune disease has been hampered because of the problems above mentioned.
We developed a new way to manipulate anti-DNA synthesis using anti-Id antibodies in combination with a cytotoxic agent, neocarzinostatin (NCS)' (19) . Anti-Id antibodies designated as DIE2 or IF5 were directed to anti-DNA antibodies that were nephritogenic in patients with systemic lupus erythematosus (SLE) (20) . This procedure was capable of manipulating anti-DNA responses through the specific elimination of Id-positive cells in a human in vitro system (21) . It was, however, unknown as to what would be evoked by this procedure in vivo. In this paper, we present a successful treatment of NZB/W F1 mice disease by using anti-Id-conjugated NCS.
Methods
Animals. NZB and NZW mice were purchased from the Shizuoka Laboratory Animal Center (Shizuoka, Japan), and maintained by brother-sister mating at the Institute for Experimental Animals, Tohoku University.
Reagents. Calf thymus DNA was obtained from Worthington Biochemicals, Freehold, NJ. The DNA was further purified into doublestranded (ds) and single-stranded (ss) DNA (22) . Human monoclonal anti-DNA antibodies (0-81 and NE-1) were obtained from B cell clones established by Epstein-Barr virus (EBV) transformation methods (23) . 0-81 antibody binds preferentially to ss-homopolymer with pyrimidine bases; NE-I reacts not only with ssDNA but also with dsDNA, RNA, and cardiolipin (24) . Two types of monoclonal anti-Id antibody (DIE2 and 1F5) to human monoclonal anti-DNA antibody (0-81 and NE-1) were obtained from mouse hybridoma using cells immunized with 0-81 or NE-1 (25 Measurement ofantibody activity. Anti-DNA or anti-DNP antibody activity was measured mainly with an enzyme-linked immunosorbent assay (ELISA) (24) . For ELISA of anti-DNA assay, wells were first treated with protamine (1 ,ug/ml) for 90 min at room temperature and then coated with DNA. The serum sample at 1:500 dilution was allowed to react with DNA or DNP-BSA coated in the wells for 90 min at 370C. After the wells were washed with PBS containing 0.05% Tween 20 and 0.2% bovine serum albumin, affinity-purified antimouse -y goat F(ab')2 or anti-mouse u goat F(ab')2 conjugated with peroxidase (Jackson Laboratories) was added. After incubation at room temperature for 90 min, the wells were washed five times and treated in the dark for 10 min with o-phenylenediamine (100 ,l per well) and absorbance was measured at 492 nm. Quantitative immunoassay for the total IgG and IgM in each sample was also performed in microplates with ELISA. A 50-Mg sample was incubated at 370C for 90 min with 50 Al of peroxidase anti-mouse y goat Ig F(ab')2 or with peroxidase anti-mouse u goat Ig F(ab')2 in a well that had been coated with mouse IgG (0.5 ug/ml) or with mouse IgM (0.5 tg/ml). Each well was washed three times with PBS and the ELISA was then performed as described above. For each assay a 15-point standard calibration curve was prepared for IgG and IgM (0.1-50 jig). Natural thymotoxic activity was also determined as follows: each sample at the appropriate dilutions was first mixed with the thymocytes from BALB/c mice and incubated at 4°C for 60 min. After washing with 0.15 M PBS, pH 7.2, containing 1% BSA, the cells were mixed with 1:20 diluted rabbit sera (Cedarlane, CA) and again incubated for 60 min at room temperature. The cytotoxity was then determined by a dye exclusion test.
Measurement ofanti-DNA-Id activity. Anti-DNA idiotypic activity was determined by absorption ofanti-DNA-binding capacity using anti-Id antibody-conjugated affinity column. Each sample was first passed through a Dl E2-or a 1F5-coupled Sepharose 4B column, and then the DNA-binding ability of the effluent was compared with those from mouse Ig-coupled Sepharose 4B columns.
Measurement ofantibody-producing or Id-positive cells. Sheep red blood cells were coupled with ssDNA, dsDNA, or BSA, using CrCI3-6H20 as described in other papers (22) . The number ofplaque-forming cells (PFC) against ssDNA or dsDNA was determined by subtracting the PFC to background sheep erythrocytes from those to ssDNA or dsDNA. The specificities of PFC to DNA were checked by inhibition studies in PFC assays in which the appropriate free ssDNA, dsDNA, D 1E2, or I F5 was added to the agar slide (22) .
Anti-DNA antibody-producing or anti-DNA-Id-positive cells were also determined by a modified enzyme-linked immunospot (ELISPOT) assay (31) . Namely, 24-well plates (no. 3024, Falcon Labware, Oxnard, CA) were incubated with I ml of ssDNA (10 gg), dsDNA (10 jig), or DNP-BSA (2 ,g) in 0.15 M PBS, pH 7.2, overnight at 4°C. For DNA-coating, plates were precoated with protamine (1 mg/ml). Each well was washed and nonspecific binding sites were then blocked by incubation of 3% BSA-Tris-buffered saline for 1 h at 37°C. After the plates were washed three times with Tris-buffered saline, spleen cells (1 X 106 in 1 ml of Dulbecco's modified Eagle's medium) were plated to the well and incubated for 4 h in a 5% CO2 at 37°C. The cells were then removed from each well and biotinated anti-mouse IgG or IgM (Jackson Laboratories) were added and incubated for 1 h at 37°C. Plates were again washed with Tris-buffered saline-0.05% Tween 20, and streptavidin alkaline phosphatase was added and incubated for I h at 37°C. Then 0.6% agarose in the development buffer including 5-bromo, 3-chloro indylyl phosphate (Sigma Chemical Co., St. Louis, MO) was added and incubated for 1 h, followed for 16 h at 4°C. Finally, the spots were counted using an inverted microscope.
Isoelectric focusing (IEF) and immunoblotting. Flat-bed IEF was carried out in a 5% polyacrylamide gel (10 X 20 X 0.1 cm) containing 6.3% pharmalytes, pH 3-11 (Pharmacia), 13% glycerol, and 6 M urea using a Pharmacia FBE-3000 system. The gel was prefocused at 8 W for 20 min at 40C (21) . Each sample, diluted to a final volume of 60 til containing 6 M urea, was applied to the gel surface using no. 1 filter paper wicks (Whatman Inc., Clifton, NJ). The gel was then focused at 30 W to a maximum of 3,000 V/h at 40C. The pH gradient was measured using a flat membrane pH electrode or IEF calibration kit. The focused gel was placed in a gel transfer holder, and blotted electrophoretically onto a nitrocellulose membrane in 0.7% acetic acid solution at 40C for 30 min at 30 V, and then for an additional 30 min at 150 V. After blotting, free binding sites on the membrane were blocked by incubation in 100 ml of 1.5% BSA in PBS containing 0.1% Tween 20 for 1 h at 370C on a rocker platform. The membrane was rinsed three times with PBS containing 1.5% BSA and 0.1% Tween 20 (washing buffer), overlayed with '25I-labeled probe (DIE2, IF5, or mouse Ig) and then incubated for 90 min at room temperature on the rocker. The membrane was rinsed with several changes of washing buffer with rocking for 15 h at room temperature, then dried and exposed to X-ray film (X-Omat, Eastman Kodak Co., Rochester, NY) at -70'C.
Statistical analysis. The data were analyzed using Student's t test and results with a P value of < 0.05 were considered to be statistically significant.
Results
Effect on survival. The survival rates in each group are shown in Fig. 1 . Renal disease seemed the final cause of death among NZB/W F. mice because the mice died soon after showing massive proteinuria (>333 mg/dl). In the first series of the experiments, 20% of the mice in the Ig-NCS group were alive at 11 mo of age and 38% in the 1F5-NCS group. Only the DIE2-NCS group differed significantly in survival (10½/2 mo; P <0.05). In the second series, both control and Ig-NCS groups had died after 7 or 8 mo of age. In contrast, all mice termed anti-Id-NCS in Fig. 1 B, which were treated with DIE2-NCS plus lF5-NCS, were living at 9 mo of age. The prolonged survival time in this group was evident since 95% of mice were still alive at 11 mo of age, compared with 45% in the other groups (101/2 mo; P < 0.01).
Urinalysis and glomerular injuries. Serial urinalysis was used to monitor the development of renal injuries in NZB/W F. mice. As demonstrated in Fig. 2 , half of Ig-NCS-treated or untreated mice had significant proteinuria (> 111 mg/dl) at 8½/2 mo ofage. The positive frequency of massive proteinuria in DIE2-NCS group was low compared with that in mouse Ig-NCS group (10 mo; P < 0.005). Most of the Ig-NCS and untreated groups in the second series became positive for massive proteinuria (> 333 mg/dl), followed by death. In contrast, treatment with DlE2-NCS pluslF5-NCS (anti-Id-NCS) prevented more significantly an early development of proteinuria (9 mo; P < 0.005). Massive proteinuria was observed in only 14% of this group by the beginning of the 10th mo of age.
However, 67% ofthe mice had significant proteinuria at1I1 mo of age.
The kidneys in each mice at 11 mo of age were examined microscopically for lesions, and the glomerular injury was evaluated by activity index and chronicity index. The results showed that the degree of glomerular damage was mild in the anti-Id-NCS group, when compared with that in the Ig-NCS or in the nontreated group (TableI). Levels of anti-DNA autoantibodies in sera. Treatment of NZB/W F1 mice with anti-Id-NCS also prevented the development of high titers of antibodies to dsDNA as well as to ssDNA (Fig. 3) . Small amounts ofanti-DNA antibodies were detected at 8 mo of age in each group. The titers of anti-DNA antibod- were similar to those in the other groups (Table II) . There was also no significant difference in the amounts of mean serum IgG among the groups.
Anti-DNA-Id activity in sera and in glomerular eluates. The quantities of anti-DNA-Id were first studied by absorption tests using anti-Id (DlE2 and 1F5)-coupled activity in sera. Fig. 3 shows that the treatment of anti-Id-NCS caused a significant decrease of Id-positive antibodies, when the absorption of anti-ssDNA antibodies was compared with those in mouse Ig-NCS and in the nontreated group (P < 0.02 and <0.01). Id in anti-dsDNA antibodies were also low in antiId-NCS groups (P < 0.05 and <0.01). Thus, the reduction of may be mainly attributed to a decrease of anti-DNA-Id-positive antibodies, which were targeted by anti-Id antibodies. It was also noted that the amounts of anti-dsDNA antibodies with irrelevant idiotypes decreased to 51% of those in mouse Ig-NCS treated mice or to 75% in untreated mice. Similarly, those of anti-ssDNA antibodies were 65% and 87% in the controls. A decreased expression of0-81 and NE-I Id in serum anti-DNA antibodies was also confirmed by an IEF analysis as demonstrated in Fig. 4 . The studies revealed that 56% or 64% in anti-Id-NCS-treated mice resulted in negative tests for 0-81-Id or NE-Id in sera. The quantities of anti-DNA idiotypes in the glomerular eluates were also studied by an absorption test (Table III) . 0-81 and NE-1-Id-positive anti-DNA antibodies shared with 24-42% of total anti-DNA antibodies in the renal eluates from the untreated lupus mice. In the eluates from anti-Id-NCS group, the amounts of anti-DNA antibodies, which mainly expressed irrelevant Id, were lower than those in both control groups.
Anti-DNA PFC in spleen. The numbers of PFC specific for DNA determinants were variable when spleen cells were used in the 11th mo. As shown in Fig. 5 , all mice in control groups had above 3 X I03 anti-DNA PFC in the spleen, whereas some in the anti-Id-NCS group had markedly decreased PFC (P < 0.01). When 2 ,eg of free anti-Id antibodies (D1 E2 and I F5) was added to spleen cells during PFC assay (blocking test), there were only half as many anti-DNA PFC as those when mouse Ig was added. However, in anti-Id-NCS group, the numbers of anti-DNA-PFC were the same whether mouse Ig or anti-Id was added (data not shown).
In vitro studies. The spleen cells were also tested for anti-DNA and anti-DNP antibody-producing ability in vitro. The cultures using the spleen cells from mouse Ig-NCS or the untreated group had 21.4±1. shown when Dl E2-or 1 F5-binding cells were directly counted by an ELISPOT assay (Table IV) . Anti-DNP responses after the stimulation of DNP-KLH in vitro were similar among the untreated, Ig-NCS, and anti-Id-NCS groups.
Discussion
In the present study, we demonstrated a successful manipulation of the production of spontaneously occurring anti-DNA antibodies in autoimmune NZB/W F. mice through anti-Id immunity. Anti-Id antibodies used were originally developed B cells from patients with SLE, especially with active lupus nephritis (21) . We have also observed that 0-81 and NE-1 Id were associated with renal lesions of SLE, based on the deposition in renal glomeruli of active lupus patients and the specific detection of circulating immune complexes involving 0-81 Id in patients with renal lesions (20) . Thus, 0-81 and NE-1 Id are markers of nephritogenic antibodies in human SLE, and anti-DNA antibodies expressing these Id may play an important role in the pathogenesis of lupus nephritis. We then proved that 0-81 and NE-1 Id were interspecies Id, distributed in murine anti-DNA antibodies as well as in humans (32) . These Id were also expressed on anti-DNA autoantibodies in NZB/W F1 mice as shown in Fig. 5 . Based on the above mentioned data, we tried to achieve selective suppression of anti-DNA antibody production in NZB/W F. mice by using D1E2 and lF5. (33) . Therefore, the chromophore, another component of NCS, can retain its pharmacological activity in an intact form after the coupling procedure (28) . After binding to Id determinants on the cell surface, the chromophore, or the active part of NCS (34, 35) , can be dissociated and easily enter the target cells and act effectively (33) . Another merit is that NCS has been widely used for cancer therapy in Japan, suggesting the possibility of clinical application. Precise information on the preparation and its merits have been given elsewhere (28) .
The administration of anti-Id-NCS was effective in suppressing lupus nephritis (Fig. 2) and in prolonging survival rates (Fig. 1) in NZB/W F1 mice. Decreased response was specific to anti-DNA responses since the levels of anti-DNP antibodies and total amounts of Ig molecules were similar among all groups (Table I ). The reduction in anti-DNA antibody synthesis seems to be mainly attributable to Id-mediated suppression as shown in Fig. 4 , where the quantities of 0-81 and NE-I Id-positive anti-DNA antibodies were markedly decreased in anti-Id-NCS-treated mice. The question arises whether suppression of anti-DNA antibodies expressing some Id may evoke an enhanced synthesis of irrelevant Id-positive antibodies in vivo. This possibility seems to be unlikely in the present system because the amounts of 0-81 and NE-l-Id-negative anti-DNA antibodies were decreased, compared to those in control mice (Fig. 4) . The targets by anti-Id-NCS treatment may be B cells because the numbers of anti-DNA PFC in the spleen were decreased in half in the anti-Id-treated mice at 11 months of age. The cells from this group also had a diminished ability to produce anti-DNA PFC in vitro. D I E2-NCS directly killed 0-81 Id-positive B cells in human in vitro system (19, 21) . Thus, the reduction may be mainly due to the elimination of Id-positive antibody-producing cells. The suppression, however, could not be explained solely by the elimination of Idpositive B cells, since Id-negative anti-DNA antibodies were also decreased in the treated mice. This is interesting from the view point of Id-related T Another is the use ofanti-Id antibodies recognizing pathogenic autoantibodies. This is based on the hypothesis that a selective manipulation ofpathogenic antibodies may result in blocking of development of tissue injuries through the autoimmune process. We recently obtained data that the numbers of nephritogenic anti-DNA antibodies are restricted in human SLE although serum anti-DNA antibodies are markedly heterogenous (20) . This indicates the possibility of controlling pathogenic antibody synthesis by a limited number of anti-Id antibodies. In fact, the above-mentioned idea is supported by the present paper, which showed that the mixture of two monoclonal anti-Id antibodies conjugated with NCS has the ability to bring about an improvement in the survival rate of NZB/W F1 mice. We failed to completely inhibit the development of lupus nephritis in NZB/W F. mice. Previous studies have demonstrated that the viral envelope glycoprotein (gp) 70-associated immune complexes are the other major factors responsible for the renal injuries in NZB/W F1 mice (36) . Anti-Id antibodies used in this experiments may not be reactive to anti-gp 70 antibodies so that the administration of anti-Id-NCS might be unable to suppress the production of gp 70-associated immune complexes. Thus, gp 70 immune complexes might be at least partly responsible for the development of immune complexes nephritis in antiId-NCS groups.
Taken together, the presented data suggest the feasibility of employing anti-Id immunity for the therapy of autoimmune diseases. Further studies to obtain human monoclonal anti-Id antibodies are in progress.
